Consensus Immatics N.V. CBOE

Stocks

IMTX

NL0015285941

Biotechnology & Medical Research

Real-time CBOE 03:21:14 25/09/26 am AEST			5-day change	1st Jan Change
8.200 ^USD	-4.65%		-0.35%	-18.02%

25/08	Immatics Announces $150 Million Underwritten Offering	MT
18/08	Immatics' Q2 Net Loss Narrows as Revenue Rises	MT

9f1d04b544.qVcvhGYbiPl25glRgiGAOXpsuK6ocx2ZBJ5iD7895x4.zwNOyyQs570GuWRj9krLCjg2wM_cBEXqVM4NVspYplHNBn7WDmnytBy8PQ~4e9c4bb393f2f5c28c880c1469c65cd0

Analysts' recommendations: Immatics N.V.

28/04	TD Cowen Initiates Immatics at Buy	MT
07/03	Deutsche Bank Lifts Price Target on Immatics to $18 From $17, Keeps Buy Rating	MT
07/01	Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says	MT
07/01	BofA Adjusts Price Target on Immatics to $17 From $14, Maintains Buy Rating	MT
20/11	Mizuho Raises Price Target on Immatics to $23 From $19, Keeps Outperform Rating	MT
18/09/25	Guggenheim Initiates Coverage on Immatics N.V With Buy Rating, $16 Price Target	MT
28/05/25	Deutsche Bank Initiates Coverage on Immatics With Buy Rating, $10 Price Target	MT
08/01/25	BofA Securities Adjusts Price Target on Immatics to $13 From $15, Maintains Buy Rating	MT
07/10/24	Piper Sandler Initiates Immatics With Overweight Rating, $19 Price Target	MT
15/05/24	Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating	MT
03/11/23	Cantor Fitzgerald Initiates Coverage on Immatics with Overweight Rating	MT
18/08/23	Mizuho Ups Price Target on Immatics to $14 From $12, Maintains Buy Rating	MT
31/03/23	Mizuho Initiates Immatics at Buy With $12 Price Target	MT
23/03/23	Chardan Adjusts Price Target on Immatics to $25 From $28, Keeps Buy Rating	MT
10/08/22	Chardan Research Adjusts Price Target on Immatics to $28 From $30, Reiterates Buy Rating	MT
03/06/22	SVB Securities Adjusts Immatics NV's Price Target to $26 from $25, Keeps Outperform Rating	MT
25/03/22	SVB Leerink Adjusts Immatics' Price Target to $25 from $32, Keeps Outperform Rating	MT
15/12/21	SVB Leerink Adjusts Immatics PT to $32 From $28, Maintains Outperform Rating	MT
15/07/21	Immatics N : SVB Leerink Adjusts Immatics NV's Price Target to $27 from $26, Keeps Outperform Rating	MT
18/03/21	Immatics N : Chardan Adjusts Immatics' Price Target to $30 From $28, Reiterates Buy Rating	MT
18/03/21	Immatics N : SVB Leerink Adjusts Immatics NV Price Target to $26 From $17, Maintains Outperform Rating	MT
21/11/20	Immatics N : BofA Securities Starts Immatics at Buy With $13 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+11.38%
	ARGENX SE					+23.5%
	INSMED INCORPORATED					+68.62%
	BIONTECH SE					+19.14%
	GENMAB A/S					+0.49%
	PHARMAESSENTIA CORPORATION					+18.92%
	EXELIXIS, INC.					-5.36%
	SUMMIT THERAPEUTICS INC.					+76.86%
	MADRIGAL PHARMACEUTICALS, INC.					+32.71%
	Average					+27.36%
	Weighted average by Cap.					+23.55%